Under construction – not a live service
Sign in
Taking people in FranceNo phase

Blood Marker TWEAK for Predicting Multiple Sclerosis Flare-Ups

Measures a blood protein called TWEAK in adults with multiple sclerosis over one year.

Plain-language title generated from the registry record
Registry title: TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis

Key facts

Where
Marseille, FranceSee the site

Where in France

  • Assistance Publique Hôpitaux de MarseilleMarseille, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Assistance Publique Hopitaux De Marseille
Trial code
NCT03974997
Record updated
23 September 2026
Original description
A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.Read full original descriptionShow less

TNF-related Weak Inducer of Apoptosis (TWEAK), a New Biomarker Predicting Inflammatory Thrust in Multiple Sclerosis

A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.

Inclusion: a first episode of inflammation and demyelination of the central nervous system affecting the optic nerve, the spinal cord, one cerebral hemisphere, or the brainstem; or confirmed multiple sclerosis; no differential diagnosis at enrollment based on clinical examination and laboratory tests; compliance with the revised 2017 Mac Donald diagnostic criteria.

Exclusion: age <18 years old; person in an emergency situation; adult who is subject to a legal protection measure (an adult under guardianship, conservatorship, or judicial protection), or who is unable to give consent; not Enrolled in a Social Security Program; pregnant or breastfeeding woman.

ClinicalTrials.gov NCT03974997